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Abstract Tumour necrosis factor-K (TNF) has a variety of
cellular effects including apoptotic and necrotic cytotoxicity.
TNF activates a range of kinases, but their role in cytotoxic
mechanisms is unclear. HeLa cells expressing elevated type II 75
kDa TNF receptor (TNFR2) protein, analysed by flow
cytometry and Western analysis, showed altered c-Jun N-ter-
minal kinase (JNK) and p38 mitogen-activated protein kinase
(p38MAPK; but not MAPK) protein content and activation.
There was greater JNK activation, but reduced p38MAPK
activation in dying cells compared to those still to enter TNF-
induced apoptosis. Moreover, cells displaying more rapid
apoptosis possess higher levels of type I 55 kDa TNFR1 receptor
isoform, but less TNFR2. These findings reveal differential
kinase activation in TNF-induced apoptotic death. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Tumour necrosis factor-K (TNF) is a member of a family of
ligands whose members also include LT-K, Apo-1/Fas ligand
and CD40 ligand [1,2]. This TNF superfamily of cytokines are
expressed mainly as type II membrane proteins which can be
cleaved proteolytically to produce a soluble form. This ligand
family activates a corresponding family of structurally related
receptors, with members of the TNF receptor (TNFR) super-
family containing common extracellular cysteine-rich repeat
structures (three to six copies). In contrast, the intracellular
domains of the TNFR superfamily are largely unrelated.
These receptors initiate signals that regulate cellular actions
including gene induction for immune responses and in£amma-
tory reactions, cell death mechanisms, proliferation, and
through excessive signalling, the pathology of a variety of
diseases [3]. Within a particular cell line TNF can initiate
two distinct pathways, one leading to cell death, and the other
to the production of ‘protective’ proteins that are anti-apo-
ptotic, with the cellular response often resulting from the bal-
ance of these opposing e¡ects [4]. This disparity of TNF-in-
duced responses is due in part to the existence of two distinct
TNFR subtypes. Type I 55 kDa TNFR (TNFR1; also known
as p55TNFR, TNFRSF1a, and CD120a) has a molecular
mass of 50^60 kDa, whereas type II 75 kDa TNFR
(TNFR2; also known as p75TNFR, TNFRSF1b, and
CD120b) has a molecular mass of 70^80 kDa [5,6]. These
receptor subtypes are expressed on the surface of most cells,
although in di¡erent amounts. TNFR1 is expressed ubiqui-
tously, whereas TNFR2 is found predominantly on haemo-
poietic and endothelial cells, showing a tightly regulated ex-
pression [7].
Signalling of the TNFR superfamily members depends on
ligand-induced oligomerisation and recruitment of adapter
proteins that lead either to gene induction via activation of
transcription factors or to apoptosis via the activation of a
proteolytic caspase cascade. What precisely determines the
balance between both major pathways is currently not known.
Distinct receptor-associating adapter proteins have been dem-
onstrated to di¡erentially interact with each receptor family
member [8,9]. TNFR1 has been shown to recruit TRADD,
FLICE, RIP, FADD, TNFR-associating factor (TRAF)-2,
ICH-1, MADD, TRIP, I-FLICE, A-29, and I-TRAF.
TRADD functions as a platform adapter that recruits several
signalling molecules to the activated receptor [8]. TNFR2, like
the TNFR1, can also recruit TRAF-2, but also utilises
TRAF-1, IAP-1, and IAP-2. Others have also observed the
direct interaction of p80TRAK and casein kinases with acti-
vated TNFR2 [9]. The role of these factors in TNF signalling
and cell death mechanisms have yet to be fully elucidated.
Extracellular signal-regulated kinases (ERKs) are central
mediators that propagate extracellular signals inside the cell,
and are activated by diverse stimuli, including cytokines such
as TNF [10]. The three mammalian ERK families activated by
TNF are: the mitogen-activated protein kinases (MAPKs),
the c-Jun N-terminal kinases (JNKs), and p38MAPK. The
p44/p42 MAPK group (also termed ERK1 and ERK2 respec-
tively) are activated by dual threonine/tyrosine phosphoryla-
tion via MAPK kinase (MEK). Once activated, MAPK medi-
ates biological responses involved in cell proliferation and
di¡erentiation by phosphorylating a number of substrates in-
cluding cytosolic phospholipase A2 (cPLA2) [11^13] and the
transcription factors c-Myc, AP-1, NF-IL6, ATF-2, and Elk-
1. The dual speci¢city kinases MKK4/SEK1 and MKK7 ac-
tivate JNKs, while p38MAPKs are activated by the MKK3/6
homologues [10]. Once activated, JNKs mediate the phos-
phorylation and activation of the transcription factors c-Jun,
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ATF-2, and Elk-1. The p38MAPK cascade is likewise in-
volved in the transcriptional regulation of ATF-2 and Elk-1
as well as CHOP and the activation of MAPK-activated pro-
tein kinases (MAPKAPK) 2/3, which in turn phosphorylate
small heat shock proteins [14].
Generally, although known to in£uence mitogenic re-
sponses or stress-related activities such as in£ammation or
ultimately cell death, the precise role of ERKs in these cellular
functions is not well understood [14]. As MAPK, p38MAPK
and JNK pathways are important in TNF-mediated signal-
ling, the aim of our study was to assess the activation state
of these kinases in human cell lines which are undergoing
TNF-induced apoptotic cell death.
2. Materials and methods
2.1. Materials
Recombinant human TNF was purchased from RpD Systems
(Abingdon, UK). Its biological activity was con¢rmed to have at least
2U107 WHO U/mg in an L929 cytotoxicity assay when comparing
TNF standards (kindly provided by Dr Meenu Wadhwa, National
Institute of Biological Standards and Controls, Potters Bar, UK).
85 kDa poly[ADP-ribose]polymerase (PARP) fragment polyclonal
antisera were purchased from BioSource International (Nivelles, Bel-
gium). Htr-9 (TNFR1) and utr-1 (TNFR2) monoclonal antisera were
bought from Bachem (Sa¡ron Walden, UK). Phospho-speci¢c MAPK
and p38MAPK antisera were from New England Biolabs (Hitchin,
UK). Phospho-speci¢c JNK antisera were from Calbiochem (CNBio-
sciences, Nottingham, UK). Non-phospho-speci¢c (pan) MAPK,
p38MAPK, JNK and the pan-PARP antisera were obtained from
Santa Cruz Biotechnology (Heidelberg, Germany). Annexin-V propi-
dium iodide (PI) cell death measurement kit was obtained from Caltag
Med Systems (Towcester, UK). p38MAPK inhibitor, SB203580, and
MEK inhibitor, PD98059, were procured from Calbiochem. All other
materials were from BDH/Merck (Poole, UK) or from Sigma Chem-
ical (Poole, UK) and were of the highest grade obtainable.
2.2. Methods
2.2.1. Cell culture. HeLa cells were co-transfected on an Eppen-
dorf Transjector 5246/InjectMan micromanipulator and microinjec-
tion system with cDNAs encoding the human TNFR2 (with permis-
sion from Werner Lesslauer, Ho¡mann La Roche, Basel, Switzerland)
and pBABE hygromycin resistance. Positive colonies were selected by
growth in Dulbecco’s modi¢ed Eagle’s medium (DMEM) with 10%
foetal bovine serum (Helena Biosciences), 1 mM L-glutamine,
100 Wg/ml penicillin, 100 Wg/ml streptomycin supplemented with 100
Wg/ml hygromycin B (Boehringer, Mannheim). Positive colonies were
expanded and characterised for TNFR2-expression levels by FACS
analysis with utr-1 monoclonal antiserum, or by [125I]TNF binding
analysis [15] (not shown). HeLa-TNFR2 stable expression cells con-
tain approximately 6000 TNFR1 receptors/cell and 68 000 TNFR2
receptors/cell.
2.2.2. Cell death measurements. Cells death measurements in 96-
well culture plates using cresyl violet as described [16]. Treatment with
the indicated combination of agents was for 24 h before ¢xation and
colorimetric determination of cell number.
2.2.3. Fluorescence-activated cell sorting (FACS) analysis. HeLa-
TNFR2 cells were grown to approximately 80% con£uence and dis-
sociated from their culture vessel with 2 ml of trypsin-free cell disso-
ciation solution (Sigma). Cells were washed once in 5 ml serum-free
DMEM and resuspended in serum-free DMEM to give a cell popu-
lation of 5U106 cells. Where necessary, cells were given two pre-per-
meabilisation washes in permeabilisation bu¡er (1UPBS (pH 7.3), 1%
(v/v) foetal calf serum, 0.1% (w/v) sodium azide, 0.1% (w/v) saponin),
so as to allow antisera access to intracellular locations. A 200 Wl
aliquot of cells was incubated on ice for 1 h in a 1:200 dilution of
primary antibody. Cells were centrifuged at 5000Ug for 2 min, super-
natant discarded then cell pellet resuspended in 200 Wl serum-free
DMEM before addition of a 1:50 dilution of secondary antibody
(FITC-labelled IgGs, Scottish Antibody Production Unit, Carluke,
UK) and incubation on ice for a further 1 h. Prior to FACS analysis,
the cells were washed three times and resuspended in 1 ml of PBS+2%
foetal bovine serum (v/v). For PI samples, nuclear staining was per-
formed on freshly-dissociated HeLa-TNFR2 cells that were ¢xed with
70% ethanol before staining with PI according to the manufacturer’s
instructions (Bender MedSystems, Vienna, Austria). FACS analysis
was performed in a Becton-Dickenson FACSCalibur machine under
standard manufacturer’s protocols [17].
2.2.4. Western blotting. Cells were treated with stimuli for the
indicated times before cell monolayers were lysed using RIPA bu¡er
(1UPBS, 1% (v/v) Nonidet P-40, 0.5% (w/v) sodium deoxycholate,
0.1% (w/v) SDS) supplemented with 0.1 mg/ml phenylmethylsulphonyl
£uoride, 10 Wg/ml aprotinin, 1 mM NaVO4. After a 30 min incubation
on ice, insoluble debris was pelleted (5 min, 10^000Ug, 4‡C) and
discarded. Cell protein concentrations were determined by Lowry
protein assay (Bio-Rad), then supplemented with 2ULaemmli loading
bu¡er (20% glycerol, 4% L-mercaptoethanol, 0.3% bromophenyl blue)
prior to 10% SDS^PAGE. Western analysis and autoradiographic
detection by enhanced chemiluminescence were performed essentially
as described [18,19].
3. Results
3.1. TNFR-induced cell death
Our studies used a model of TNF-induced cytotoxicity that
displays enhanced apoptotic cell death in response to low
concentrations of recombinant wild-type TNF. HeLa-
TNFR2 cells express endogenous TNFR1 and stably express
some ten-fold more exogenous TNFR2 protein. These cells
respond to TNF treatment by undergoing relatively rapid ap-
optotic cell death [20], with near complete cell death seen in
24 h with 5 ng/ml TNF treatment (Fig. 1A). FACS analysis
allows us to observe the death of HeLa-TNFR2 cells and
distinguish the more granular dying cells, from the less gran-
ular, less opaque healthy cells which have still to progress into
apoptotic cell death. Comparison of the cells which are
healthy (gated region R1, Fig. 1B) to those which are dying
after 16 h TNF treatment (gated region R2, Fig. 1B) allows us
to distinguish the biochemical and cellular changes which oc-
cur in the induction of TNF-stimulated apoptotic death in
HeLa-TNFR2 cells. Phosphatidylserine presentation on the
extracellular surface of a cell is a characteristic of apoptotic
cell death [21^23]. We see greater expression of phosphatidyl-
serine in dying HeLa-TNFR2 cells, as judged by the greater
amount of annexin-V binding (which binds to expressed phos-
phatidylserine) in dying cells as compared to healthy, unapo-
ptotic cells (Fig. 1C). This is also true of PI DNA stain which
binds better to DNA in leaky late apoptotic cells, and which
shows greater £uorescence in dying HeLa-TNFR2 cells as
compared to healthy cells (Fig. 1C). Furthermore, quantita-
tion of the cell cycle pro¢le with PI revealed the number of
cells with hypodiploid characteristics (M1 region, Fig. 1C)
indicative of apoptotic DNA fragmentation. 0, 0.5 and 16 h
TNF treatment resulted in 4.1, 7.7 and 21.7% of R1-gated
(healthy) cells being hypodiploid, whereas R2-gated (dying)
cells showed 22.9, 21.6 and 62.5% cells being hypodiploid
respectively. TNF-induced caspase protease activation is a
mediator of cell damage and death [24]. The caspase family
of proteases function to cleave key proteins, including the
DNA repair enzyme PARP from its 116 kDa holoenzyme
into an inactive 85 kDa fragment (Fig. 1D). An antiserum
speci¢c for the cleaved 85 kDa fragment also con¢rmed the
greater presence of cleaved PARP enzyme in dying HeLa-
TNFR2 cells compared to healthy cells (Fig. 1C,D).
3.2. TNFR activation and cell death
Our data revealed there to be a signi¢cant alteration in
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TNFR levels upon TNF treatment (Fig. 2). Treatment of
HeLa-TNFR2 cells with TNF resulted in a time-dependent
reduction in the level of TNFR1 and TNFR2 protein, as
measured by FACS and Western analyses. TNFR1 levels
were reduced after an 16 h treatment with TNF, with minimal
e¡ect of a 30 min TNF treatment. However, TNFR2 levels
were reduced markedly after only a 30 min TNF treatment
period (Fig. 2). This rapid reduction in cell surface TNFR2
protein levels suggests that TNFR2 protein is proteolytically
cleaved upon stimulation by TNF. This ¢nding was borne out
in FACS experiments in which TNF-treated HeLa-TNFR2
cells were pre-permeabilised before TNFR2 antiserum addi-
tion. It was found that TNFR2 receptor was not internalised
or rapidly processed into an intracellular store, as most cel-
lular TNFR2 antiserum binding was lost from the cell com-
pletely with 30 min TNF treatment (data not shown). This
¢nding was also true of endogenous TNFR2 protein, with
comparable studies in KYM-1 human rhabdomyosarcoma
Fig. 1. Analysis of apoptotic cell death markers in TNF-treated HeLa-TNFR2 cells. A: Concentration^response cell death relationship of pa-
rental HeLa and HeLa-TNFR2 cells measured after 24 h TNF treatment. The data are the mean þ S.E.M. of at least four determinations in
the presence of 1 Wg/ml cycloheximide. B: Flow cytometry measurement of HeLa-TNFR2 cells þ 50 ng/ml TNF treatment for 18 h before
FACS analysis of side scatter (Vgranularity) and forward scatter (Vsize), including a typical indication of an R1-gated region (healthy) and
R2-gated region (dying). C: Comparison of HeLa-TNFR2 cells treated for the indicated times with 50 ng/ml TNF then histogram measurement
of annexin-V, PI, or 85 kDa PARP fragment £uorescence intensities in R1- and R2-gated subsets of cells. M1 region indicates apoptotic cells
with hypodiploid characteristics which are to the left of the sharp G1/G0 then G2/M peaks with their intervening S-phase portion. D: Western
analysis of PARP degradation in HeLa-TNFR2 cells treated for the indicated times with 50 ng/ml TNF in the presence of 1 Wg/ml cyclohexi-
mide to inhibit de novo protein synthesis. Data are from a representative experiment similar to at least two other determinations with essen-
tially the same ¢ndings.
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cells showing similar ¢ndings in TNF-stimulated TNFR2 pro-
tein loss (not shown). Not surprisingly, TNFR2 levels were
low in healthy or dying cells that were treated with TNF, and
did not appear to alter appreciably comparing FACS inten-
sities or in Western blots of 30 min (healthy) or 16 h TNF-
treated (dying) cells (Fig. 2). The level of TNFR1 protein was
reduced signi¢cantly in the total cell population by 16 h TNF
treatment (thought to be through a non-shedding internalisa-
tion process [6]), however comparison of healthy and dying
cells by FACS showed that an appreciably higher level of
TNFR1 was present in HeLa-TNFR2 cells that were under-
going apoptotic cell death.
Fig. 2. Analysis of TNFRs in TNF-treated HeLa-TNFR2 cells. A: Flow cytometry measurement of HeLa-TNFR2 cells treated for the indi-
cated times with 50 ng/ml TNF then histogram measurement of TNFR subtype levels in R1- and R2-gated subsets of cells. B: Western analysis
of TNFR1 and TNFR2 protein in HeLa-TNFR2 cells treated for the indicated times with 50 ng/ml TNF. Data are from a representative ex-
periment similar to at least two other determinations with essentially the same ¢ndings.
Fig. 3. Western analysis of JNK, MAPK and p38MAPK activation and levels in TNF-treated HeLa-TNFR2 cells. Western analysis of JNK,
MAPK and p38MAPK activation using phospho-speci¢c antisera, or total JNK, MAPK and p38MAPK protein levels using the indicated pan-
ERK antisera. HeLa-TNFR2 cells were treated for the indicated times with 50 ng/ml TNF. Data are from a representative experiment similar
to at least two other determinations with essentially the same ¢ndings.
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3.3. TNF activation of ERKs and cell death
We see that HeLa-TNFR2 cells treated for 30 min by TNF
results in the activation of JNK, MAPK and p38MAPK ki-
nase pathways, as assessed in Western blots using phospho-
speci¢c activated ERK antisera (Fig. 3). A 30 min TNF treat-
ment did not in£uence the total levels of ERKs as judged by
the pan-ERK antibodies. Longer term (16 h) treatment with
TNF markedly reduced the total levels of JNK and
p38MAPK stress kinases. However, although MAPK and
p38MAPK activation status had returned to or reduced below
basal levels, it was seen that JNK activation in 16 h TNF-
treated cells was still raised, despite there being a reduction in
total JNK protein levels in the entire cell population.
Generally, we observed by FACS that comparing dying
HeLa-TNFR2 cells to healthy cells, MAPK could be activated
by TNF, but the levels of MAPK activation and protein levels
were unchanged in dying cells (Fig. 4). Once again, as seen in
the Western analysis, JNK was activated on a short- and
long-term basis by TNF plus it was observed that dying cells
had signi¢cantly greater amounts of JNK activity and protein
than healthy cells. A direct measurement of JNK activity
(rather than phosphorylation-dependent activation that is ac-
tually measured by the phospho-speci¢c antisera) would be
helpful, however only total populations (healthy and dying
combined) can be measured in conventional kinase activity
assays. To this end, we also measured phosphorylation of a
downstream target of JNK, c-Jun, using a phospho-speci¢c
c-Jun antiserum (serine 63-speci¢c, New England Biolabs) and
found that dying TNF-treated HeLa-TNFR2 cells also con-
tained greater levels of phosphorylated c-Jun compared to
healthy cells (0, 0.5 and 16 h TNF treatment resulted in
17.8, 19.7 and 54.4% of R1-gated (healthy) cells with high
phospho-c-Jun binding, whereas R2-gated (dying) cells
showed 33.0, 29.8 and 78.4% cells with high phospho-c-Jun
binding respectively). These ¢ndings of elevated JNK and
c-Jun activation were in direct contrast to the activation and
total protein levels of p38MAPK in TNF-treated HeLa-
TNFR2 cells, which although activated by TNF treatment,
were found to be signi¢cantly reduced in dying HeLa-
TNFR2 cells as assessed by FACS analysis (Fig. 4). Unfortu-
nately, phospho-speci¢c antisera for downstream targets of
MAPK and p38MAPK are not currently available and kinase
activity cannot presently be assessed for these ERK members.
The above ¢ndings clearly indicate a role for increased JNK
activity and reduced p38MAPK activity in HeLa-TNFR2 cells
that are more rapidly undergoing TNF-induced apoptosis.
Unfortunately, pharmacological experiments were inconclu-
sive mainly due to the lack of any commercially available
JNK inhibitors, plus the fact that a selective p38MAPK in-
hibitor, SB203580 (5 WM), was by itself toxic to HeLa-
Fig. 4. FACS analysis of JNK, MAPK and p38MAPK activation and levels in TNF-treated HeLa-TNFR2 cells. Flow cytometry analysis of
JNK, MAPK and p38MAPK activation using phospho-speci¢c antisera, or total JNK, MAPK and p38MAPK protein levels using the indi-
cated pan-ERK antisera. HeLa-TNFR2 cells were treated for the indicated times with 50 ng/ml TNF before FACS analysis of antisera £uores-
cence intensities in R1- and R2-gated subsets of cells. Data are from a representative experiment similar to at least two other determinations
with essentially the same ¢ndings.
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TNFR2 over a prolonged period of exposure (54 þ 7% of cells
dead after 24 h treatment, mean þ S.E.M., n = 4). However, it
was clear that activation of JNK by the metabolic cell stres-
sor, anisomycin (25 WM) could enhance HeLa-TNFR2 cell
death (51 þ 12 and 90 þ 8% of cells dead without and with
24 h exposure to 50 ng/ml TNF respectively, means þ S.E.M.,
n = 4^6). Moreover, whereas MAPK activation by aurintricar-
boxylic acid (50 WM) resulted in mitogenesis of HeLa cells
(187 þ 9% of control cell number, n = 6), inhibition of
MAPK activation with the compound PD98059 (25 WM),
achieved greater TNF-induced apoptotic cell death in HeLa-
TNFR2 cells (65 þ 5% and 92 þ 7% of cells dead without and
with 24 h exposure to 50 ng/ml TNF respectively, means
þ S.E.M., n = 4^6). These pharmacological experiments sug-
gest that MAPK may have a role in mitogenesis, and that
JNK may be involved in apoptotic death processes.
4. Discussion
TNF is able to control a wide variety of cellular responses
from proliferation and di¡erentiation, through to in£amma-
tion and death [3]. TNF achieves these di¡erent e¡ects by
acting on two TNFRs which are di¡erentially expressed
throughout each cell type. It is becoming apparent that the
signalling mechanisms employed by these TNFRs may be
di¡erent depending on the cell type in which they are acti-
vated and the intracellular machinery that the TNFRs access,
which again is dependent on the proteins present in each in-
dividual cell type. In addition, each of the protein components
accessed by the TNF signalling events may be regulated them-
selves in a way which is reliant on the physiological status or
environmental experience of that particular cell which encoun-
ters TNF ligand. One such signalling component is the ERK
family of protein kinases which can direct a variety of bio-
chemical and cellular processes [10,14,25]. Here we have
shown that there is regulation of each of the di¡erent ERK
kinase families and that there may be di¡erential activation
processes occurring in TNF-induced apoptotic cell death.
Use of £ow cytometry allows us to isolate subpopulations
of cells and analyse a parameter within that cell subset. Here
we distinguish between healthy regular low granularity cells
(gated as region R1) and those cells which have altered side
scatter properties to a more opaque granular appearance
(gated as region R2) which is characteristic of TNF-induced
apoptotic cell death morphology. We con¢rm the greater ap-
optotic characteristics in the dying subset of cells by measur-
ing greater phosphatidylserine presentation (as measured by
annexin-V binding), cell permeability and nuclear condensa-
tion (as measured by propidium iodide £uorescence) and cas-
pase-dependent cell protein destruction (as measured by the
cleavage of PARP holoenzyme into an 85 kDa inert frag-
ment). Curiously, whilst measuring the TNFR subtypes in
these cells we observed long-term destruction of TNFR1
(probably through internalisation and digestion [6]), and
short-term removal of TNFR2, through a mechanisms which
is probably proteolytic shedding of the receptor into a soluble,
non-membrane-associated form [7], that is seen with both the
exogenous TNFR2 protein in HeLa-TNFR2 cells, and with
endogenous TNFR2 protein in KYM-1 cells. Given that the
presence of TNFR2 in HeLa cells allows greater and more
rapid TNF-induced apoptosis, the abrupt loss of this receptor
isoform seems at odds with its cellular actions. However, its
rapid activation and long-term e¡ectiveness of TNFR2 is seen
when HeLa-TNFR2 cells are treated for 5 min with TNF
(which is then removed and antagonistic antisera added)
and then still die 24 h later, hence the TNFR2-signalling cas-
cades are already initiated before shedding of the receptor
occurs.
The role that ERKs play in proliferation and apoptotic
death processes is unresolved [14,25]. It is thought that
MAPK is more involved in mitogenic responses [26^30] in
some cell types with a possible role in cell death in other cells
[31]. Although activated by TNF, we found no role for
MAPK in the TNF-induced apoptosis we investigated. We
did see marked stimulation of mitogenesis with a MAPK ac-
tivator, and enhancement of TNF-induced cell death with the
speci¢c MEK inhibitor, PD98059. Others found that
p38MAPK may have a role in proliferation [4,32^34], or in
cell death [35^38]. Our ¢ndings support a role for p38MAPK
in proliferative processes judged on the reduction of
p38MAPK activity and total protein content in TNF-treated
apoptotic cells. Unfortunately our results using a p38MAPK
inhibitor were inconclusive as the compound was signi¢cantly
toxic to the cells. More of a role for JNK in apoptosis has
been reported [39^43] than a role for the kinase in prolifer-
ative responses [37,44,45]. Our data heavily indicate a role for
JNK in the mediation of apoptotic cell death. Not only do we
see prolonged JNK activation (as was reported to be crucial
elsewhere [46]), but the pharmacological data support JNK
not being protective against TNF-stimulated cell death. Un-
fortunately, no commercial inhibitors of JNK are currently
available to help us support our contention of a role for
JNK in TNFR-mediated apoptotic cell signalling.
These ¢ndings indicate that the regulation of di¡erent mem-
bers of the ERK superfamily occurs by TNFRs. Moreover,
the kinase regulation was seen in individual subsets of dying
cells and their observed regulation supports a role for the
regulation of these kinases in apoptotic cell death cellular
processes.
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